SETH LERNER to Androgen Antagonists
This is a "connection" page, showing publications SETH LERNER has written about Androgen Antagonists.
Connection Strength
0.477
-
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 07 01; 7(7):e2419966.
Score: 0.213
-
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
Score: 0.209
-
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. Eur Urol Oncol. 2025 Jun; 8(3):612-615.
Score: 0.055